ClinicalTrials.gg
CompletedNCT00316199Updated Jun 17, 2009Results posted

Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer

A Phase 2 interventional study of gemcitabine and paclitaxel in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 3 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.

Enrollment
50th of 90
60 · median 68
Started
2006
with 7 others
Phase 2
65 of 95
none open now
Registered
41st of 95
by date
Lead sponsor
20 of 95
Eli Lilly and Company

Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 50th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2006, is one of 65 in phase 2, and was the 41st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing gemcitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the response rate to a gemcitabine-paclitaxel combination administered on a 3-weekly schedule in Chinese patients with unresectable, locally recurrent breast cancer or metastatic breast cancer.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients of Chinese origin with or cytologically proven diagnosis of breast cancer.
  • Unresectable, locally recurrent breast cancer or stage IV disease.
  • Have at least one as defined by (RECIST) criteria.
  • Performance Status of 0 or 1 on the (ECOG) Scale
  • Treatment with an anthracycline-based chemotherapy regimen in the /neoadjuvant setting with subsequent disease relapse.

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy for unresectable, locally advanced breast cancer or disease.
  • Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy.
  • Known or suspected or second primary that is clinically detectable at the time of consideration for study enrollment.
  • Active infection or other serious condition.
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    A

    Drug: gemcitabine · Drug: paclitaxel

Interventions

  • 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression

    Also known as: LY188011, Gemzar

  • 175 mg/m2, intravenous (IV), every 21 days until disease progression

06

What researchers measure

Primary outcomes

  1. Best Overall Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

    Time frame: baseline to measured progressive disease (tumor assessments were performed every 2 cycles during study therapy, or 3 months during post-therapy until disease progression, or up to 12 months after enrollment)

Secondary outcomes

  1. Time to Treatment Failure

    Defined as time from enrollment to the date of death due to any cause, measured disease progression, treatment discontinuation for undocumented progression, early treatment discontinuation for toxicity or other reason, or new anticancer treatment started.

    Time frame: baseline to stopping treatment

  2. Progression-Free Survival

    Defined as the time from enrollment to the date of objective disease progression or death on study, whichever occurs first. Censoring was determined based on US-FDA 2005 draft guidance on clinical endpoints.

    Time frame: baseline to measured progressive disease or death (tumor assessments were performed every 2 cycles during study therapy, or 3 months during post-therapy until disease progression, or up to 12 months after enrollment)

  3. Duration of Response

    Measured from the time of first documentation of complete response (CR) or partial response (PR), whichever status is first recorded, until the date of objective disease progression or death on study, whichever occurs first, with censoring defined in the same way as for progression-free survival.

    Time frame: time of response to measured progressive disease or death (tumor assessments were performed every 2 cycles during study therapy, or 3 months during post-therapy until disease progression, or up to 12 months after enrollment)

  4. Overall Survival Probability

    Original outcome was overall survival = time from date of enrollment to date of death due to any cause. Survival time was censored at date of last contact for participants who were still alive or lost to follow-up. Because only 8 participants had documented death while on study, results are reported as 6- and 12-month overall survival probability.

    Time frame: baseline to date of death from any cause

07

Results

Posted Jun 11, 2009

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine + Paclitaxel
Started60
Completed48
Not completed12
Withdrew: Adverse event2
Withdrew: Death8
Withdrew: Lost to follow-up2

Outcome measures

PrimaryBest Overall Tumor Response

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

Time frame:
baseline to measured progressive disease (tumor assessments were performed every 2 cycles during study therapy, or 3 months during post-therapy until disease progression, or up to 12 months after enrollment)
Reported as:
Number · participants
Best Overall Tumor Response
participantsGemcitabine + Paclitaxel
Complete Response (CR)2
Partial Response (PR)27
Stable Disease (SD)20
Progressive Disease (PD)7
Early Death from Malignant Disease0
Death from Toxicity0
Early Death from Other Causes0
Unknown2
SecondaryTime to Treatment Failure

Defined as time from enrollment to the date of death due to any cause, measured disease progression, treatment discontinuation for undocumented progression, early treatment discontinuation for toxicity or other reason, or new anticancer treatment started.

Time frame:
baseline to stopping treatment
Reported as:
Median · months
Time to Treatment Failure
monthsGemcitabine + Paclitaxel
Time to Treatment Failure4.5 (4.1 to 5.3)
SecondaryProgression-Free Survival

Defined as the time from enrollment to the date of objective disease progression or death on study, whichever occurs first. Censoring was determined based on US-FDA 2005 draft guidance on clinical endpoints.

Time frame:
baseline to measured progressive disease or death (tumor assessments were performed every 2 cycles during study therapy, or 3 months during post-therapy until disease progression, or up to 12 months after enrollment)
Reported as:
Median · months
Progression-Free Survival
monthsGemcitabine + Paclitaxel
Progression-Free Survival7.6 (5.8 to 8.8)
SecondaryDuration of Response

Measured from the time of first documentation of complete response (CR) or partial response (PR), whichever status is first recorded, until the date of objective disease progression or death on study, whichever occurs first, with censoring defined in the same way as for progression-free survival.

Time frame:
time of response to measured progressive disease or death (tumor assessments were performed every 2 cycles during study therapy, or 3 months during post-therapy until disease progression, or up to 12 months after enrollment)
Reported as:
Median · months
Duration of Response
monthsGemcitabine + Paclitaxel
Duration of Response5.6 (4.4 to 7.6)
SecondaryOverall Survival Probability

Original outcome was overall survival = time from date of enrollment to date of death due to any cause. Survival time was censored at date of last contact for participants who were still alive or lost to follow-up. Because only 8 participants had documented death while on study, results are reported as 6- and 12-month overall survival probability.

Time frame:
baseline to date of death from any cause
Reported as:
Number · percent
Overall Survival Probability
percentGemcitabine + Paclitaxel
6-Month Overall Survival Probability97
12-Month Overall Survival Probability87

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine + Paclitaxel———
Most frequent serious events
Most frequent serious events
EventGemcitabine + Paclitaxel
Femur fractureInjury, poisoning and procedural complications1/60
Most frequent other events
Showing 10 of 29
Most frequent other events
EventGemcitabine + Paclitaxel
AlopeciaSkin and subcutaneous tissue disorders50/60
NeutropeniaBlood and lymphatic system disorders46/60
LeukopeniaBlood and lymphatic system disorders42/60
MyalgiaMusculoskeletal and connective tissue disorders35/60
Peripheral sensory neuropathyNervous system disorders28/60
ArthralgiaMusculoskeletal and connective tissue disorders21/60
FatigueGeneral disorders19/60
Alanine aminotransferase increasedInvestigations16/60
NauseaGastrointestinal disorders13/60
VomitingGastrointestinal disorders13/60

Baseline characteristics

Age Continuous
Age Continuous(years)Gemcitabine + Paclitaxel
Mean46.9 ± 8.96
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine + Paclitaxel
Female60
Male0
Region of Enrollment
Region of Enrollment(participants)Gemcitabine + Paclitaxel
China60
Disease Stage at Study Entry
Disease Stage at Study Entry(participants)Gemcitabine + Paclitaxel
Stage IIIB6
Stage IV54
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(participants)Gemcitabine + Paclitaxel
0 - Fully Active30
1 - Ambulatory, Restricted Strenuous Activity30
Menopausal Status
Menopausal Status(participants)Gemcitabine + Paclitaxel
Pre-Menopausal29
Peri-Menopausal7
Post Menopausal22
Missing2
Pathological Diagnosis
Pathological Diagnosis(participants)Gemcitabine + Paclitaxel
Undifferentiated Breast Carcinoma1
Infiltrating Lobular Carcinoma0
Infiltrating Ductal Breast Carcinoma55
Adenocarcinoma3
Comedocarcinoma0
Missing1
Race/Ethnicity
Race/Ethnicity(participants)Gemcitabine + Paclitaxel
East Asian (Chinese)60

2 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100071, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guang Zhou, 510060, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200032, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2006
First posted
Apr 20, 2006
Start
Apr 2006
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Jun 11, 2009
Last update
Jun 17, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00316199
First posted
Apr 20, 2006
Start date
Apr 2006
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jun 11, 2009
Last update
Jun 17, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Paclitaxel

Start the discussion